Literature DB >> 15023421

Survival signaling in resting B cells.

Alina Patke1, Ingrid Mecklenbräuker, Alexander Tarakhovsky.   

Abstract

The survival of mature resting B cells in the periphery depends on signaling from the B-cell receptor (BCR) and the B-cell activating factor of the TNF family receptor (BAFF-R). Engagement of both receptors promotes NF-kappa B activity, which contributes to B-cell survival through different pathways. BCR signaling leads to activation of the inhibitor of NF-kappa B kinase (IKK) complex via Carma1, Bcl10 and MALT1, whereas BAFF-R engagement promotes processing of NF-kappa B2 protein p100, which is dependent on NF-kappa B-inducing kinase (NIK) and IKK alpha. Proximal signaling intermediates are potentially common to both pathways. We suggest that BCR and BAFF-R survival signaling are mutually dependent. In addition, we propose that BAFF-R signaling enhances the expression of survival genes through direct chromatin modifications in NF-kappa B target gene promoters.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023421     DOI: 10.1016/j.coi.2004.01.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  20 in total

1.  Regulation of B cell activating factor (BAFF) receptor expression by NF-ΚB signaling in rheumatoid arthritis B cells.

Authors:  Yun Ju Woo; Bo Young Yoon; Joo Yeon Jhun; Hye Jwa Oh; Se Won Min; Mi La Cho; Sung Hwan Park; Ho Youn Kim; Jun Ki Min
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

2.  Transcription factor Zfx controls BCR-induced proliferation and survival of B lymphocytes.

Authors:  Teresita L Arenzana; Matthew R Smith-Raska; Boris Reizis
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

3.  Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.

Authors:  Makiko Kobayashi; Ikuko Takahashi-Suzuki; Toshiyasu Shimomura; Yoshikazu Iwasawa; Hiroshi Hirai
Journal:  Invest New Drugs       Date:  2010-06-04       Impact factor: 3.850

4.  NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.

Authors:  Wen-Hui Hu; Julie S Pendergast; Xian-Ming Mo; Roberta Brambilla; Valerie Bracchi-Ricard; Fang Li; Winston M Walters; Bas Blits; Li He; Sandra M Schaal; John R Bethea
Journal:  J Biol Chem       Date:  2005-06-10       Impact factor: 5.157

Review 5.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

6.  Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.

Authors:  Mitsufumi Nishio; Tomoyuki Endo; Nobuhiro Tsukada; Junko Ohata; Shinichi Kitada; John C Reed; Nathan J Zvaifler; Thomas J Kipps
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

7.  A splicing variant of NME1 negatively regulates NF-κB signaling and inhibits cancer metastasis by interacting with IKKβ.

Authors:  Dong-Joo You; Cho Rong Park; Hyun Bok Lee; Mi Jin Moon; Ju-Hee Kang; Cheolju Lee; Seong-Hyun Oh; Curie Ahn; Jae Young Seong; Jong-Ik Hwang
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

Review 8.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 9.  Signalling crosstalk in B cells: managing worth and need.

Authors:  Michael P Cancro
Journal:  Nat Rev Immunol       Date:  2009-09       Impact factor: 53.106

10.  Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells.

Authors:  Shengli Xu; Jianxin Huo; Koon-Guan Lee; Tomohiro Kurosaki; Kong-Peng Lam
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.